Quick Take
Zentalis Pharmaceuticals (ZNTL) intends to raise $130 million from an IPO of its common stock, according to an amended S-1/A registration statement.
The company is advancing a pipeline of potential drug treatments for breast cancer, solid tumors and other cancers.
ZNTL has two significant collaborations and the IPO is priced at the high end of the typical range for Phase 1 / 2 stage biopharmas with large market opportunities.
The stock may be appropriate for long-term hold life science investors.
Company & Technology
New York, New York-based Zentalis was founded